Pricing Log in Create free account
Saturday 17 October 2026 Export RDNT’s income statement to Excel — free account

RadNet, Inc.

RDNT Healthcare Diagnostics & Research

RadNet, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 billion, up 11.5% from fiscal 2024. In the quarter to June 2026, revenue grew 25.0%, EPS fell 47.4%, free cash flow fell 43.2% and total debt rose 21.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

68.53 1.88 −2.67%
Market cap
$5.5B
P/E
0.0×
Fwd P/E
279×
Dividend yield
—
F-score
3/9
Altman Z
2.04
Beneish M
−2.62
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 11.35
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 1 1 — — 1 — — 3 — — — —
Insider Ownership 9.47%

Capital & Financial Ratios $m

Market Cap 5,540.00
Revenue 2,268.93
Net Income 19.27
Free Cash Flow 74.36
Net Debt 579.88
Current Ratio 1.48
Debt/Equity 0.94
P/E ratio 0.00
Fwd P/E 279.00 (above 35: high)
P/S ratio 2.35
P/B ratio 3.82
Past 5Y EPS Growth —
This Y EPS Growth 31.87% (at or above 15%: strong)
Next Y EPS Growth 72.41% (at or above 15%: strong)
Next Y revenue growth 22.88% (at or above 10%: strong)
Next 5Y EPS Growth 41.72% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.6×, against a ten-year median of 1.4×; over the ten years it ranged from 1.0× in 2017 to 3.6× in 2024.
P/S against its own 10 years 85.29%
10-year low 10-year high
P/B against its own 10 years 44.75%
10-year low 10-year high
EV/Sales against its own 10 years 86.33%
10-year low 10-year high
EV/FCF against its own 10 years 85.82%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 343 740 767 726
Receivables 164 186 200 242
Inventory — — — —
Other 25 42 13 7
579 1,019 1,032 1,036
2023 2024 2025 Q'26
Payables 343 351 422 490
ST’ Debt — 25 25 —
Other 16 44 70 91
437 480 587 698

Compound Annual Growth %

10y 5y 3y
Sales 9.68% 13.74% 12.57%
Cash Flow 16.12% 5.03% 26.84%
Earnings 0.00% 0.00% 0.00%
Book Value 43.56% 39.32% 40.25%

Revenue $m

Mar Jun Sep Dec Year
’26 576 623 — — —
’25 471 498 523 548 2,040
’24 432 460 461 477 1,830
’23 391 404 402 420 1,617
’22 342 354 350 384 1,430
’21 315 334 333 333 1,315
’20 282 191 292 308 1,072
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 79 94 — — —
’25 41 120 53 84 299
’24 17 116 57 43 233
’23 33 68 31 89 221
’22 1 65 27 54 146
’21 28 31 42 49 149
’20 41 91 39 63 234
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 9 38 — — —
’25 (7) 67 (8) 34 87
’24 (40) 69 16 0 45
’23 (23) 29 (21) 49 44
’22 (36) 33 (26) 34 31
’21 (2) 8 (63) 65 7
’20 (10) 78 26 47 140
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.43) 0.10 — — —
’25 (0.50) 0.19 0.07 (0.01) (0.25)
’24 (0.04) (0.04) 0.04 0.07 0.04
’23 (0.36) 0.12 0.25 (0.03) 0.05
’22 0.05 0.13 0.01 (0.02) 0.17
’21 0.18 0.05 0.30 (0.07) 0.46
’20 (0.33) (0.21) 0.12 0.11 (0.29)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 4.66 5.25 9.65 9.97 5.81 17.68 12.03 17.82 33.44 45.00

Analyst estimates 2026–2028

Powerpack
High 7.98 11.90 16.54 20.45 23.45 38.84 30.43 37.97 93.65 85.84
People
People Employees 7,285 7,440 7,869 8,498 8,327 8,973 9,067 10,288 11,021 11,264
Revenue/emp, $m 0.12 0.12 0.12 0.14 0.13 0.15 0.16 0.16 0.17 0.18
Income, $m
Income, $m Revenue 885 922 975 1,154 1,072 1,315 1,430 1,617 1,830 2,040
Gross margin, % 12.29 12.99 11.03 13.39 9.88 14.58 11.59 13.69 13.62 11.54
EBT 12 26 39 30 (1) 59 43 39 45 32
EBT margin, % 1.41 2.86 3.95 2.57 (0.08) 4.48 3.00 2.40 2.45 1.56
Net income 8 2 38 23 (2) 44 34 30 39 17
Depreciation 72 70 77 152 163 178 191 196 211 217
Per share, $
Per share, $ Revenue 19.13 19.67 20.27 23.23 21.06 25.05 25.40 25.43 25.05 27.13
Earnings 0.16 0.00 0.67 0.30 (0.29) 0.47 0.19 0.05 0.04 (0.25)
Cash flow 1.98 3.03 2.43 2.10 4.59 2.85 2.60 3.47 3.19 3.97
Capex (1.26) (1.28) (1.44) (1.47) (1.83) (2.71) (2.05) (2.78) (2.57) (2.82)
Free cash flow 0.72 1.75 0.99 0.63 2.76 0.14 0.55 0.70 0.62 1.16
Book value 1.13 1.49 4.16 4.69 5.08 6.59 8.73 12.79 15.52 18.03
Shares, m 46 47 48 50 51 52 56 64 73 75
Valuation, ×
Valuation, × P/E 36.89 0.00 15.41 70.00 0.00 64.06 103.56 3,456.00 2,328.00 0.00
P/S 0.34 0.51 0.50 0.87 0.93 1.20 0.73 1.36 2.79 2.63
P/B 5.77 6.74 2.44 4.33 3.86 4.57 2.14 2.70 4.50 3.96
EV/Sales 1.01 1.08 1.14 1.50 1.51 1.72 1.28 1.70 2.94 2.79
EV/FCF 26.89 12.10 23.46 55.16 11.51 185.15 59.31 1,196.26 1,759.54 126.94
Cash, $m
Cash, $m Operating cash flow 92 142 117 104 234 149 146 221 233 299
Capex (58) (60) (69) (73) (93) (142) (116) (177) (188) (212)
Free cash flow 33 82 47 31 140 7 31 44 45 87
Balance, $m
Balance, $m Working capital 63 44 (31) (86) (128) (51) (100) 142 540 445
Total debt 639 609 672 760 722 820 909 812 1,016 1,090
Net debt 619 558 662 720 620 686 782 469 276 323
Shareholders’ equity 52 70 200 233 258 346 491 813 1,133 1,356
Returns, %
Returns, % ROA 0.86 0.01 3.26 1.07 (0.86) 1.29 0.47 0.12 0.09 (0.53)
ROIC 3.59 4.98 2.24 4.58 2.54 5.00 2.28 4.81 4.64 2.31
ROE 16.34 0.09 23.87 6.81 (6.04) 8.18 2.54 0.47 0.29 (1.50)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

RadNet, Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
QGEN QIAGEN N.V. $9.5B 23.6× 17.5× +0.28% (above 0%: growing) +7.94% (above 0%: growing) +30.45% (above 0%: growing) 63.62% 24.75% Compare
TWST Twist Bioscience Corporation $9.5B — (loss-making) — (loss-making) +23.24% (above 0%: growing) n/m −7.23% (below 0%: shrinking) 52.76% (30.65%) Compare
GRAL GRAIL, Inc. $6.1B — (loss-making) — (loss-making) +25.72% (above 0%: growing) n/m −4.95% (below 0%: shrinking) (28.12%) (388.89%) Compare
RDNT RadNet, Inc. $5.5B — (loss-making) 279× +24.99% (above 0%: growing) −47.37% (below 0%: shrinking) −43.22% (below 0%: shrinking) 14.14% 6.34%
SHC Sotera Health Company $5.2B 31.4× 23.7× +9.18% (above 0%: growing) +533.33% (above 0%: growing) +60.56% (above 0%: growing) 55.38% 33.23% Compare
BLLN BillionToOne, Inc. $4.9B 95.0× 99.4× +64.40% (above 0%: growing) n/m +400.65% (above 0%: growing) 70.45% 5.03% Compare
ADPT Adaptive Biotechnologies Corporation $4.1B — (loss-making) — (loss-making) +21.53% (above 0%: growing) n/m +42.04% (above 0%: growing) 71.82% (22.04%) Compare
VCYT Veracyte, Inc. $3.6B 29.9× 45.1× +15.49% (above 0%: growing) n/m +32.95% (above 0%: growing) 72.21% 15.29% Compare
CDNA CareDx, Inc. $3.5B 29.7× 2,967× +52.23% (above 0%: growing) n/m +223.42% (above 0%: growing) 73.50% 85.81% Compare
Median of peers $5.0B 29.9× 45.1× +22.39% — +37.50% 67.04% 10.16%

All 52 Diagnostics & Research stocks →

RadNet, Inc. (RDNT) key facts

  • Strength: RadNet, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 billion, up 11.5% from fiscal 2024.
  • RadNet, Inc. (RDNT) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, RDNT traded at $68.53, a market capitalization of $5.5 billion.
  • Return on equity was −1.50% and debt-to-equity 0.94.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 2.04 (grey zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

RadNet, Inc. (RDNT) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/RDNT · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com